Zai Lab Limited American Depositary Shares
ZLABStock
$20.75−17.46%52W
Market Cap$17.54B
P/E—
Div yield—
Beta0.86
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)3.73%
Price vs S&P 500 (4W)10.08%
VGM Score55.18
Market Capitalization$17.54B
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.93
3.93
3.93
3.93
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ZLABZai Lab Limited American Depositary Shares | C | C | C | $20.75 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Zai Lab is a biopharmaceutical company developing proprietary therapeutics in oncology, autoimmune disease, and infectious disease. The company's clinical pipeline is focused on targeted antibody-drug conjugates, including programs for solid tumors, small cell lung cancer, and neuroendocrine cancers. Key candidates include ZL-1218, ZL-1310, ZL-6301, and ZL-6201, addressing multiple tumor types with novel mechanisms of action.